Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

about

Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

Item

http://www.wikidata.org/entity/Q39157481

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

@en

Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

@nl

type

Item

label

Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

@en

Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

@nl

prefLabel

Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

@en

Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

@nl

P1476

Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.

@en

P2093

Josee-Lyne Ethier

http://www.w3.org/2001/XMLSchema#string

Rebecca M Prince

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Mechanisms of osteolytic bone metastases in breast carcinoma.

Adjuvant ovarian suppression in premenopausal breast cancer.

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

P2888

s11912-017-0577-6

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-017-0577-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eitan Amir

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28251493

http://www.w3.org/2001/XMLSchema#string